Treatment of Ovarian Carcinoma With DNP-Modified Autologous Tumor Vaccine

NCT00003386 Phase 2 TERMINATED

RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.

Details

Lead sponsor	Gynecologic Oncology Group
Phase	Phase 2
Status	TERMINATED
Start date	1999-07

Conditions

• Ovarian Cancer

Interventions

• BCG vaccine
• autologous tumor cell vaccine
• carboplatin
• cisplatin
• cyclophosphamide
• paclitaxel
• dinitrophenyl
• surgical procedure

Countries

United States, Canada